| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.85 [0.71, 1.01] | | < 1 | | 0% | 1 study (1/-) | 96.6 % | NA | not evaluable | | crucial | - |
| progression or deaths (PFS) | 1.23 [0.88, 1.72] | | < 1 | | 0% | 1 study (1/-) | 10.9 % | NA | not evaluable | | important | - |
| DOR | 0.44 [0.25, 0.75] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 0.59 [0.43, 0.80] | | > 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (grade 3-4) | 0.55 [0.40, 0.78] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.51 [1.02, 2.22] | | < 1 | | 0% | 1 study (1/-) | 1.9 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 1.67 [1.23, 2.28] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.57 [1.06, 2.32] | | < 1 | | 0% | 1 study (1/-) | 1.3 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.32 [0.20, 0.50] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 0.25 [0.18, 0.35] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 1.85 [0.17, 20.46] | | < 1 | | 0% | 1 study (1/-) | 31.0 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 1.30 [0.83, 2.03] | | < 1 | | 0% | 1 study (1/-) | 12.6 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.92 [0.02, 46.53] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 2.78 [0.29, 26.84] | | < 1 | | 0% | 1 study (1/-) | 19.0 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 7.44 [0.39, 141.31] | | < 1 | | 0% | 1 study (1/-) | 9.3 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 0.92 [0.02, 46.53] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.02 [0.01, 0.10] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Arthralgia TRAE (grade 3-4) | 5.56 [0.28, 111.52] | | < 1 | | 0% | 1 study (1/-) | 13.4 % | NA | not evaluable | | non important | - |
| Arthritis TRAE (grade 3-4) | 1.84 [0.06, 55.15] | | < 1 | | 0% | 1 study (1/-) | 36.4 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.65 [0.20, 2.08] | | < 1 | | 0% | 1 study (1/-) | 76.5 % | NA | not evaluable | | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.46 [0.02, 13.75] | | < 1 | | 0% | 1 study (1/-) | 67.1 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 7.44 [0.39, 141.31] | | < 1 | | 0% | 1 study (1/-) | 9.3 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 1.84 [0.06, 55.15] | | < 1 | | 0% | 1 study (1/-) | 36.4 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.69 [0.15, 3.10] | | < 1 | | 0% | 1 study (1/-) | 68.7 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 1.84 [0.06, 55.15] | | < 1 | | 0% | 1 study (1/-) | 36.4 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.67 [0.56, 5.05] | | < 1 | | 0% | 1 study (1/-) | 18.0 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 0.92 [0.02, 46.53] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.68 [0.23, 2.00] | | < 1 | | 0% | 1 study (1/-) | 75.6 % | NA | not evaluable | | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.30 [0.03, 2.95] | | < 1 | | 0% | 1 study (1/-) | 84.6 % | NA | not evaluable | | non important | - |
| Gastritis TRAE (grade 3-4) | 1.84 [0.06, 55.15] | | < 1 | | 0% | 1 study (1/-) | 36.4 % | NA | not evaluable | | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 0.92 [0.02, 46.53] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 1.84 [0.06, 55.15] | | < 1 | | 0% | 1 study (1/-) | 36.4 % | NA | not evaluable | | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 0.46 [0.02, 13.75] | | < 1 | | 0% | 1 study (1/-) | 67.1 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.92 [0.02, 46.53] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 5.56 [0.28, 111.52] | | < 1 | | 0% | 1 study (1/-) | 13.4 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 3.70 [0.17, 82.33] | | < 1 | | 0% | 1 study (1/-) | 20.7 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 1.85 [0.34, 10.18] | | < 1 | | 0% | 1 study (1/-) | 24.0 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.78 [0.29, 26.84] | | < 1 | | 0% | 1 study (1/-) | 19.0 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 15.41 [2.03, 116.88] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.92 [0.02, 46.53] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.04 [0.00, 0.63] | | < 1 | | 0% | 1 study (1/-) | 98.8 % | NA | not evaluable | | non important | - |
| Myocarditis TRAE (grade 3-4) | 0.92 [0.02, 46.53] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 0.92 [0.02, 46.53] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.11 [0.01, 0.90] | | < 1 | | 0% | 1 study (1/-) | 97.9 % | NA | not evaluable | | non important | - |
| Nephritis TRAE (grade 3-4) | 1.84 [0.06, 55.15] | | < 1 | | 0% | 1 study (1/-) | 36.4 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.01 [0.00, 0.09] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 3.70 [0.17, 82.33] | | < 1 | | 0% | 1 study (1/-) | 20.7 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.11 [0.01, 2.16] | | < 1 | | 0% | 1 study (1/-) | 92.4 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.84 [0.06, 55.15] | | < 1 | | 0% | 1 study (1/-) | 36.4 % | NA | not evaluable | | non important | - |
| Pruritic rash TRAE (grade 3-4) | 1.84 [0.06, 55.15] | | < 1 | | 0% | 1 study (1/-) | 36.4 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 3.70 [0.17, 82.33] | | < 1 | | 0% | 1 study (1/-) | 20.7 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.92 [0.13, 6.57] | | < 1 | | 0% | 1 study (1/-) | 53.3 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 7.44 [0.39, 141.31] | | < 1 | | 0% | 1 study (1/-) | 9.3 % | NA | not evaluable | | non important | - |
| Sepsis TRAE (grade 3-4) | 0.46 [0.02, 13.75] | | < 1 | | 0% | 1 study (1/-) | 67.1 % | NA | not evaluable | | non important | - |
| Stevens-Johnson syndrome TRAE (grade 3-4) | 0.92 [0.02, 46.53] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 1.84 [0.06, 55.15] | | < 1 | | 0% | 1 study (1/-) | 36.4 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.02 [0.00, 0.29] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.84 [0.06, 55.15] | | < 1 | | 0% | 1 study (1/-) | 36.4 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.36 [0.07, 1.89] | | < 1 | | 0% | 1 study (1/-) | 88.4 % | NA | not evaluable | | non important | - |
